Hypofractionated RT Cuts Grade 3 Skin Toxicity to 1.7% From 12.2% Post-Mastectomy

Hypofractionated radiotherapy cut grade 3 acute skin toxicity to 1.7% from 12.2% compared with conventional fractionation while matching five-year locoregional control at 1.7% versus 2.2% in a randomized phase III trial of 1,494 patients, Targeted Onc reported.

The noninferiority margin was met with a hazard ratio of 0.69 (95% CI, 0.32–1.51; P = .017) for locoregional recurrence after a median follow-up of 58.1 months, according to the study published online October 19 in the Journal of Clinical Oncology.

Xiaofang Wang, MD, PhD, and colleagues at Fudan University Shanghai Cancer Center randomly assigned women with high-risk operable breast cancer to 42.56 Gy in 16 fractions or 50 Gy in 25 fractions, both covering the chest wall and internal mammary nodes.

“Increased institutional throughput and capacity, enhanced patient convenience, and reduced financial toxicity” are practical advantages of the shorter course, Wang and coauthors wrote in the paper.

Five-year distant metastasis–free survival was 92.3% with hypofractionation versus 92.7% with conventional radiotherapy (HR, 1.00; 95% CI, 0.68–1.47; P = .987). Breast cancer recurrence–free survival was 91.8% versus 92.3% (HR, 0.99; 95% CI, 0.69–1.45; P = .980), disease-free survival 88.5% versus 89.4% (HR, 1.05; 95% CI, 0.76–1.44; P = .769), and overall survival 95.1% versus 96.1% (HR, 1.21; 95% CI, 0.72–2.01; P = .476).

Grade 1–2 skin pain occurred in 7.7% of hypofractionated patients versus 23.3% with conventional treatment (P < .001). Pruritus rates were 26.7% versus 35.2% (P = .001). Late grade 1–2 hyperpigmentation was 21.8% versus 27.2% (P = .019).

Sixteen-Fraction PMRT With IMN Irradiation Noninferior in High-Risk Breast Cancer
Photo: cancernetwork.com

Grade 2 or higher radiation pneumonitis (2.0% vs 2.1%) and pulmonary fibrosis (1.3% in both arms) were low and comparable. No ischemic heart disease events, grade 4 toxicities, or treatment-related deaths were recorded. Clinical lymphedema rates were similar at 24.0% versus 23.0% (P = .575).

The locoregional recurrence benefit held across T stage, N stage, molecular subtype, age, histology, and grade. Five-year locoregional recurrence was below 1% for N1 disease and 4% or lower for N2–3 disease. In hormone receptor–negative/HER2–negative patients, rates were 6.4% with hypofractionation and 8.2% with conventional treatment.

A dedicated analysis of 133 patients with breast reconstruction showed no increased complication risk with the 16-fraction schedule.

Eligible women were 18 to 70 years old, had undergone mastectomy with negative margins and axillary lymph node dissection with at least 10 nodes removed, and had pathologic T1–4/N2–3, T3–4/N1, or T1–2/N1 disease with at least one high-risk feature such as age under 40, grade 3 histology, lymphovascular invasion, hormone receptor–negative status, or HER2 overexpression, CancerNetwork reported. Patients who received neoadjuvant chemotherapy were excluded. Nearly all participants (99.9%) received adjuvant chemotherapy.

The authors cited several constraints: exclusion of neoadjuvant chemotherapy patients limits applicability to current practice where pathologic complete response may omit radiotherapy; all patients underwent axillary lymph node dissection rather than sentinel node biopsy; deep inspiration breath hold was used only in selected patients; the single-center design may limit generalizability; patients with N3b or N3c disease were not represented; and low event rates reduced statistical power. Longer follow-up is needed to assess late cardiac effects.

Endpoint HypoRT (16 fractions) ConvRT (25 fractions) Hazard Ratio (95% CI) P value
5-year locoregional recurrence 1.7% 2.2% 0.69 (0.32–1.51) .017
5-year DMFS 92.3% 92.7% 1.00 (0.68–1.47) .987
5-year BCRFS 91.8% 92.3% 0.99 (0.69–1.45) .980
5-year DFS 88.5% 89.4% 1.05 (0.76–1.44) .769
5-year OS 95.1% 96.1% 1.21 (0.72–2.01) .476
Grade 3 acute skin toxicity 1.7% 12.2% — <.001

Sixteen daily fractions over roughly three weeks, compared with 25 fractions over five weeks for conventional radiotherapy.

No. The trial met its noninferiority endpoint for locoregional recurrence at five years, with nearly identical distant metastasis–free and overall survival rates.

Grade 3 acute skin toxicity dropped from 12.2% to 1.7%. Moderate skin pain, itching, and late hyperpigmentation were also significantly lower.

A prespecified analysis of 133 reconstructed patients found no increase in complications with the 16-fraction regimen.

Fudan University Shanghai Cancer Center, founded on March 1, 1931, as the Sino-Belgian Radium Institute, was the first cancer specialty hospital in China. It became affiliated with Shanghai Medical College in 1954 and merged into Fudan University in 2000. The center operates 1,100 beds and treats more than 590,000 outpatients and 22,000 inpatients annually, and houses the Shanghai Key Laboratory of Breast Cancer.

Patients who received neoadjuvant chemotherapy, those with N3b or N3c nodal disease, and those managed with sentinel node biopsy alone were excluded.